Table 1. Main clinical and hematological characteristics of CMML patients at diagnosis (n=56).
| Variable | Median (range) | N (%) |
|---|---|---|
| Age, years | 72 (48-89) | 22/56 (39) |
| <70 | 34/56 (61) | |
| ≥70 | ||
| Gender | 37/56 (66) | |
| Male | 19/56 (34) | |
| Female | ||
| FAB classification | 46/56 (82) | |
| Myelodysplastic (CMML-MD) | 10/56 (18) | |
| Myeloproliferative (CMML-MP) | ||
| WHO classification | 49/56 (87) | |
| CMML-1 | 7/56 (13) | |
| CMML-2 | ||
| Hemoglobin level, g/dL | 12.1 (7.2-16.1) | 8/56 (14) |
| <10 | 48/56 (86) | |
| ≥10 | ||
| Leukocyte count, x109/L | 8.0 (3.2-45.0) | 46/56 (82) |
| <13 | 10/56 (18) | |
| ≥13 | ||
| Platelet count, x109/L | 139.0 (25.0-481.0) | 18/56 (32) |
| <100 | 38/56 (68) | |
| ≥100 | ||
| Neutrophil count, x109/L | 4.1 (0.8-30.2) | 9/56 (16) |
| <1.8 | 47/56 (84) | |
| ≥1.8 | ||
| Blasts in BM, % | 2.0 (0.0-15.0) | 53/56 (95) |
| <10 | 3/56 (5) | |
| ≥10 | ||
| RBC transfusion dependency | 50/56 (89) | |
| No | 6/56 (11) | |
| Yes | ||
| Splenomegaly | 34/43 (79) | |
| No | 9/43 (21) | |
| Yes | ||
| Cytogenetics | 51/56 (91) | |
| Normal karyotype | 3/56 (5) | |
| Isolated -Y | 2/56 (4) | |
| Uninformative CC | ||
| CPSS risk group [17] | 42/56 (75) | |
| Low | 9/56 (16) | |
| Intermediate-1 | 5/56 (9) | |
| Intermediate-2 | ||
| GFM CMML model [15] | 37/56 (66) | |
| Low | 17/56 (30) | |
| Intermediate | 2/56 (4) | |
| High | ||
| Progression to AML | 40/56 (71) | |
| No | 16/56 (29) | |
| Yes |
BM: bone marrow; RBC: red blood cell; Uninformative CC: cases with no metaphases; AML: acute myeloid leukemia